Limited Efficacy of Thrombolytics for Pump Thrombosis in Durable Left Ventricular Assist Devices

Area of Science:

• Cardiology
• Medical Devices
• Pharmacology

Background:

• Left ventricular assist device (LVAD) implantation is a critical therapy for advanced heart failure.
• Pump thrombosis is a significant complication following LVAD implantation, impacting device function and patient outcomes.
• Thrombolytic therapy is one treatment option for LVAD pump thrombosis, but its efficacy and safety remain areas of investigation.

Purpose of the Study:

• To evaluate the efficacy and safety of thrombolytic therapy for left ventricular assist device (LVAD) pump thrombosis.
• To assess outcomes including survival, adverse events, and the need for subsequent interventions after thrombolysis for LVAD pump thrombosis.

Main Methods:

• A retrospective review of adult patients who underwent continuous-flow LVAD implantation between 2004 and 2018 at a single center.
• Identification of patients who developed pump thrombosis and received thrombolytic therapy, direct pump exchange, or heparin.
• Analysis of primary outcomes (1-year survival, thrombolytic success) and secondary outcomes (adverse events, freedom from bleeding/stroke).

Main Results:

• Of 341 LVAD patients, 10.8% developed pump thrombosis; 70.2% received thrombolytic therapy.
• Thrombolytic therapy was successful in only 11.5% of patients, with 69.2% requiring subsequent pump exchange.
• Adverse events included major bleeding (11.5%) and new stroke (7.7%); 1-year survival was 63.1%.

Conclusions:

• Thrombolytic therapy for LVAD pump thrombosis demonstrates limited efficacy and carries risks of major bleeding and stroke.
• Most patients treated with thrombolytics ultimately require device exchange, highlighting the need for refined patient selection criteria.
• Further research is needed to optimize management strategies for LVAD pump thrombosis, potentially favoring earlier pump exchange in select patients.